Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

CompanyDeals

AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang

CompanyR&D

Insilico Medicine Nominates AI-Discovered ISM9077 as 32nd Preclinical Candidate Targeting Ophthalmic and Inflammatory Diseases

BeOne Medicines Reports Record Q2 2026 Revenue of $1.7B, Driven by Brukinsa Growth and Raises Full-Year Guidance
Company

BeOne Medicines Reports Record Q2 2026 Revenue of $1.7B, Driven by Brukinsa Growth and Raises Full-Year Guidance

Merck Reports Q2 2026 Sales of $16.6B, Driven by Keytruda Growth and Winrevair Surge as Company Raises Full-Year Guidance
Company

Merck Reports Q2 2026 Sales of $16.6B, Driven by Keytruda Growth and Winrevair Surge as Company Raises Full-Year Guidance

CompanyDrug

Eli Lilly’s KRAS G12C Inhibitor Olomorasib Receives Second FDA Breakthrough Therapy Designation for Advanced Pancreatic Cancer

Pfizer Reports Q2 2026 Revenue of $15.0B, Raises Full-Year Guidance as Launched and Acquired Products Surge 18%
Company

Pfizer Reports Q2 2026 Revenue of $15.0B, Raises Full-Year Guidance as Launched and Acquired Products Surge 18%

CompanyDrug

CSPC Pharmaceutical’s NDA for Anbenitamab-HB1801 Combination Accepted by China NMPA as Neoadjuvant Therapy for HER2+ Breast Cancer

Biogen Reports Q2 2026 Revenue of $2.74B, Growth Portfolio Surges 24% Led by Strong LEQEMBI and SKYCLARYS Performance
Company

Biogen Reports Q2 2026 Revenue of $2.74B, Growth Portfolio Surges 24% Led by Strong LEQEMBI and SKYCLARYS Performance

Bayer Reports Q2 2026 Sales of EUR 10.87B, Driven by Strong Nubeqa and Kerendia Growth Despite Xarelto and Eylea Patent Expirations
Company

Bayer Reports Q2 2026 Sales of EUR 10.87B, Driven by Strong Nubeqa and Kerendia Growth Despite Xarelto and Eylea Patent Expirations

Takeda Reports Q1 FY2026 Revenue of JPY 1.22 Trillion, Outlines Growth Strategy Centered on Three Key Pipeline Assets
Company

Takeda Reports Q1 FY2026 Revenue of JPY 1.22 Trillion, Outlines Growth Strategy Centered on Three Key Pipeline Assets

CompanyDrug

Leads Biolabs’ Trispecific T-Cell Engager LBL-051 Enters Phase Ia Trial for Refractory Autoimmune Diseases Through Oblenio Bio Partnership